Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2029
[188 Pages Report] The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.
To know about the assumptions considered for the study, Request for Free Sample Report
Impact of Covid-19 on Human Microbiome Market
The COVID-19 pandemic has created massive disruptions to clinical trial research across the world. As in other aspects of life, the virus has severely affected the ability to conduct trials in safe and effective ways. This is especially true when considering that trials often deal with vulnerable populations who are most at risk from exposure to COVID-19. Seres Therapeutics SER-287 development activity was adversely impacted by the COVID-19 pandemic and by multiple clinical sites halting non-essential procedures, including endoscopies. Similarly, COVID-19 has adversely impacted and could continue to adversely impact the businesses of other companies, including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostic products. However, with the relaxation of government restrictions related to the pandemic and the emergence of virtual clinical trials, R&D activities started their recovery from 2021 onward. New research activities establishing an association between gut microbiota composition and the levels of cytokines and inflammatory markers of COVID-19 have been mentioned below:
- COVID-19 is primarily a respiratory illness. However, there is significant evidence that individuals with dysbiosis in the GI tract were more prone to COVID-19 disease.
- The gut microbiome is also being linked to disease severity. Further studies are trying to establish whether perturbations in microbiome composition can permanently counter the effects of the SARS-CoV-2 virus.
Human Microbiome Market Dynamics
Driver: Increasing focus on human microbiome therapeutics development
Human gut microbiomes play a major role in improving the efficacy of therapeutic compounds. Over the years, studies have shown that the right combination of microbes in the human body is beneficial for treating different conditions. This association between microbes and specific disease states could generate new opportunities for drug developers (or vaccine manufacturers). Microbes are rich sources of enzymes, owing to which they can be used in various therapeutic applications, such as the search for novel therapies.
In the last decade, microbiome therapy has gained widespread importance. During a 10-year timespan (fiscal years 20072016), the National Institutes of Health (NIH) invested USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research activities outside of the HMP over fiscal years 20122016. Similarly, the European Commission established Metagenomics of the Human Intestinal Tract project (MetaHIT), which is mainly focused on gut bacteria. From 2008 to 2012, ~USD 15 million was invested in this project. From 2012 to 2018 ~USD 14 million (EUR 12 million) was invested in MetaCardis (Metagenomics in Cardiometabolic Diseases), which is a major EU-funded research project that investigated the role of gut microbes in cardiometabolic diseases (CMDs). Similarly, Horizon 2020 is one of the biggest EU Research and Innovation programs with funding of nearly USD 96.9 million (80 billion) available over seven years (2014 to 2020).
Many human microbiome-based product companies are awarded funds to accelerate the development of therapeutics drugs. For instance, in 2020, Vedanta Biosciences (US) received funding from the Biomedical Advanced Research and Development Authority (BARDA) of USD 7.4 million, with the potential for an additional USD 69.5 million to advance the clinical development of VE303 for high-risk Clostridioides difficile infection (CDI). Similarly, in 2020, Finch Therapeutics (US) raised USD 90 million in Series D financing from new and existing investors for the development of CP101 through the final stages of clinical development and regulatory submission in Clostridioides difficile infection. The funding will also be used to advance its platform and pipeline, including the initiation of Phase 1b studies evaluating FIN-211 for autism spectrum disorder (ASD) and CP101 for chronic hepatitis B (HBV). Similar funding and investments with a focus on microbiome research for therapeutics development are expected to drive the growth of the human microbiome market in the coming years.
Opportunity: Increasing collaborations between public-private organizations
With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.
Challenge: Government regulations
The FDA has not approved any probiotics as a live biotherapeutic product (a biological product other than a vaccine that contains live organisms used to prevent or treat a disease or condition in humans). However, there are FDA-regulated foods, including dietary supplements, containing probiotics that are legally available, though these products cannot lawfully be marketed to cure, mitigate, treat, or prevent any diseases.
Probiotic supplements are being aggressively marketed in retail stores and over the Internet. Although no probiotic has been approved for therapeutic purposes by the FDA as of now, some are undergoing clinical trials and may soon be marketed as biologics or other drugs. The current FDA regulatory requirements are not customized for probiotics. Looking at the future market potential for probiotics, there is a possibility that the FDA may come up with certain regulations for them, which will require research/clinical trials. It has been discussed that probiotics that make drug claims should be exposed to the same requirements as other drugs under the Abbreviated New Drug Application (ANDA) process. This will also allow probiotics to be excused from Phase l trials, the first step in clinical testing, and will have adequate evidence of safety. This may hamper the growth of the human microbiome market since big investors will have to invest more in R&D.
The FDA is considering changing the way it characterizes probiotics. This will help reduce the number of unsubstantiated probiotic claims, help consumers make informed decisions, and encourage more research on probiotics. Small molecules such as those developed by Microbiome Therapeutics may be able to go through the standard drug regulatory pathway. However, there may be a different or new set of regulatory hurdles for genetically modified bacteria. Other issues, including intellectual property rights for naturally occurring bacteria, may also restrict the launch of new products in the market.
Restraints: Barriers in proving the causal link between dysbiosis and diseases
The human body is home to a diverse community of symbiotic, commensal, and pathogenic microorganisms, collectively known as the microbiota. Various studies also suggested that only 30-40 species as the bulk of microbiota are shared among individuals. Analyzing specific bacteria from among trillions of species can be a highly challenging task. High-throughput omics technologies can identify the exact bacterial species involved and provide an understanding of how homeostasis between humans and microbes is maintained. According to human microbiome research, dysbiosis of microbiomes results in some of the most chronic and lifestyle diseases, such as obesity, diabetes, and various digestive disorders.
The current approaches for identifying microbial markers for diagnostic purposes need to rely on comparisons with parallel control groups of healthy individuals. Selecting the correct microbial chassis for a microbiota-based therapeutic is challenging, as it is difficult to predict which microbe is best suited for any given application.
While studies suggested that alteration in gut microbiota compositions is associated with disease conditions, but a direct co-relationship remains debatable in humans. The cause-effect relationship of microbiota dysbiosis and diseases rely mainly on data of experimental models, which may not be true for each individual.
The therapeutics segment to account for the largest share of the human microbiome market in 2023
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment to account for the largest share of the human microbiome market in 2023. The increase in funding for R&D into microbiome-based therapies worldwide is the major factor driving the growth of this application segment. In addition, technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes are also supporting market growth.
By disease, the infectious diseases segment is expected to grow at the highest CAGR during the forecast period.
Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. The infectious disease segment is expected to register the highest growth rate during the forecast period. Increasing cognizance of the ill-effects of antibiotic use on the natural flora (such as disruptions) has highlighted the need for specific bacterial-targeted therapy for infectious diseases. The rising incidence of infections due to microbial dysbiosis, as a result of antibiotic treatment, and the increasing number of clinical trials for the development of target-specific microbiome-based therapies are the major factors driving the growth of this segment.
By technology, the genomics segment is expected to grow at the highest CAGR during the forecast period.
On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to register the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market.
North America accounted for the largest share of the human microbiome market.
In 2023, North America accounted for the largest share of the overall market, followed by Europe. Factors such as the increasing incidences of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and the increasing number of microbiome research & clinical activities are responsible for driving the growth of the market in North America
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
The major players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), Second Genome (US), Vedanta BioSciences (US), and Synlogic (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
Human Microbime Market :20232029 |
|
Base year considered |
Human Microbiome Research Spending Market:2021 |
|
Forecast period |
Human Microbime Market :20232029 |
|
Forecast units |
Values (USD Million) |
|
Segments covered |
Human Microbiome MarketProduct, Disease, Application, Type, and Region |
|
Segments covered |
Human Microbiome Research Spending Market Technology |
|
Geographies covered |
Human Microbiome Market: North America (US & Canada), Europe (UK, Germany, France, and RoE) APAC (China, Japan, India, RoAPAC), and RoW |
|
Companies covered |
ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), Evelo Biosciences (US), OptiBiotix Health (UK), Synlogic (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), BiomX (Israel), DuPont (US), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US) |
Based on product, the human microbiome market is segmented as follows:
- Probiotics
- Prebiotics
- Diagnostic Tests
- Drugs
- Other Products
Based on disease, the human microbiome market is segmented as follows:
- Infectious Diseases
- Endocrine and Metabolic Disorders
- Gastrointestinal Diseases
- Cancer
- Other Diseases (cardiovascular diseases, neurological disorders, dermatology diseases, immune-modulated disorders, and hematological disorders.
Based on application, the human microbiome market is segmented as follows:
- Therapeutics
- Diagnostics
Based on type, the human microbiome market is segmented as follows:
- FMT
- Peptide
- Live Biotherapeutic Product
- Others
Based on region, the human microbiome market is segmented as follows:
- North America
- US
- Canada
- Europe
- Asia Pacific
- Rest of the World (RoW)
Based on the technology, the human microbiome research spending market is segmented as follows:
- Sequencing
- 16s rRNA sequencing method
- Whole-genome sequencing method
- Other Sequencing methods (shotgun metagenomic sequencing, transcriptomics, and targeted sequencing.)
- Other Genomic Technologies (Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays)
Recent Developments:
- In 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi Medical Co. To help tackle the obesity epidemic, the companys GoFigure and SlimBiome Medical weight management products will be available in the KSA from early 2022 through the new agreement with Nahdi.
- In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharmas Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.
- In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds
Frequently Asked Questions (FAQ):
Who are the leading players in the human microbiome market?
Some of the leading players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), Second Genome (US), Vedanta BioSciences (US), and Synlogic (US).
What are the major drivers and challenges in the human microbiome market?
Market growth is largely driven by the increasing focus on the development of human microbiome therapy. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth.
What are the major product segments in the human microbiome market?
The human microbiome market products include probiotics, prebiotics, diagnostic tests, drugs, and other products. The other products include foods, medical foods, synbiotics, and next-generation therapeutics, among others.
What is the COVID-19 impact on the human microbiome market?
The COVID-19 has adversely impacted companys businesses, including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostics products .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 26)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET
1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME RESEARCH SPENDING MARKET)
1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME MARKET)
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 32)
2.1.1 SECONDARY DATA
2.1.2 PRIMARY SOURCES
FIGURE 1 BREAKDOWN OF PRIMARIES: HUMAN MICROBIOME MARKET
2.2 MARKET DATA ESTIMATION AND TRIANGULATION
FIGURE 2 DATA TRIANGULATION METHODOLOGY
2.2.1 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET)
FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE (USD MILLION): FINAL MARKET SIZE
2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 5 FINAL CAGR PROJECTIONS (2023−2029)
2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR HUMAN MICROBIOME MARKET
FIGURE 6 HUMAN MICROBIOME MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH
2.3 INSIGHTS FROM PRIMARIES
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
2.4 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY (Page No. - 39)
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
FIGURE 9 HUMAN MICROBIOME MARKET SHARE, BY APPLICATION, 2029
FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMAN MICROBIOME MARKET
4 PREMIUM INSIGHTS (Page No. - 42)
4.1 HUMAN MICROBIOME: MARKET OVERVIEW
FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE MARKET GROWTH
4.2 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2029)
FIGURE 13 FMT TO DOMINATE HUMAN MICROBIOME MARKET IN 2023
4.3 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2023)
4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (20232029)
FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 45)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Rising industry-academia collaborations for microbiome research
5.2.1.2 Increasing focus on human microbiome therapeutics development
5.2.1.3 Human microbiome as a validated target for drug development
5.2.1.4 Development of human microbiome-based tests for early disease detection & diagnosis
5.2.2 MARKET RESTRAINTS
5.2.2.1 Barriers in proving the causal link between dysbiosis and diseases
5.2.2.2 Negative clinical data will adversely impact public perception of microbiomes
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Increasing collaborations between public-private organizations
5.2.4 MARKET CHALLENGES
5.2.4.1 Government regulations
5.2.4.2 Lack of expertise and inadequate research
5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE HUMAN MICROBIOME MARKET
5.4 REGULATORY ANALYSIS
5.4.1 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED DRUGS
5.4.2 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED FOODS
5.5 PATENT ANALYSIS
6 HUMAN MICROBIOME MARKET, BY APPLICATION (Page No. - 56)
6.1 INTRODUCTION
TABLE 1 HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
6.2 THERAPEUTIC APPLICATIONS
6.2.1 AVAILABILITY OF FUNDING FOR MICROBIOME-BASED THERAPEUTIC PRODUCTS DEVELOPMENT TO DRIVE MARKET GROWTH
TABLE 2 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 20232029 (USD MILLION)
TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 20232029 (USD MILLION)
TABLE 4 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 20232029 (USD MILLION)
TABLE 5 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 20232029 (USD MILLION)
6.3 DIAGNOSTIC APPLICATIONS
6.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH
TABLE 6 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 20232029 (USD MILLION)
TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 20232029 (USD MILLION)
TABLE 8 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 20232029 (USD MILLION)
TABLE 9 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 20232029 (USD MILLION)
7 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY (Page No. - 62)
7.1 INTRODUCTION
TABLE 10 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 20212029 (USD MILLION)
7.2 GENOMICS
TABLE 11 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 20212029 (USD MILLION)
TABLE 12 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 20212029 (USD MILLION)
TABLE 13 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 14 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 15 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 20212029 (USD MILLION)
7.2.1 SEQUENCING
TABLE 16 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 20212029 (USD MILLION)
TABLE 17 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 20212029 (USD MILLION)
TABLE 18 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 20212029 (USD MILLION)
TABLE 19 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 20212029 (USD MILLION)
TABLE 20 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 20212029 (USD MILLION)
7.2.1.1 16S rRNA Sequencing Method
7.2.1.1.1 Cost-effectiveness to propel identification of bacterial strains
TABLE 21 16S RRNA SEQUENCING METHOD, BY REGION, 20212029 (USD MILLION)
TABLE 22 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 20182025 (USD MILLION)
TABLE 23 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 20212029 (USD MILLION)
TABLE 24 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 20212029 (USD MILLION)
7.2.1.2 Whole-Genome Sequencing (WGS)Method
7.2.1.2.1 WGS to generate accurate reference genomes for microbial identification
TABLE 25 WGS METHOD, BY REGION, 20212029 (USD MILLION)
TABLE 26 NORTH AMERICA: WGS METHOD, BY COUNTRY, 20212029 (USD MILLION)
TABLE 27 EUROPE: WGS METHOD, BY COUNTRY, 20212029 (USD MILLION)
TABLE 28 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 20212029 (USD MILLION)
7.2.1.3 Other Sequencing Methods
TABLE 29 OTHER SEQUENCING METHODS, BY REGION, 20212029 (USD MILLION)
TABLE 30 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 31 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 32 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY, 20212029 (USD MILLION)
7.2.2 OTHER GENOMIC TECHNOLOGIES
TABLE 33 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 20212029 (USD MILLION)
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 20212029 (USD MILLION)
TABLE 35 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 20212029 (USD MILLION)
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 20212029 (USD MILLION)
7.3 PROTEOMICS
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 37 PROTEOMICS, BY REGION, 20212029 (USD MILLION)
TABLE 38 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 39 EUROPE: PROTEOMICS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 40 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 20212029 (USD MILLION)
7.4 METABOLOMICS
7.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS TO DRIVE MARKET GROWTH
TABLE 41 METABOLOMICS, BY REGION, 20212029 (USD MILLION)
TABLE 42 NORTH AMERICA: METABOLOMICS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 43 EUROPE: METABOLOMICS, BY COUNTRY, 20212029 (USD MILLION)
TABLE 44 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 20212029 (USD MILLION)
8 HUMAN MICROBIOME MARKET, BY TYPE (Page No. - 76)
8.1 INTRODUCTION
TABLE 45 HUMAN MICROBIOME MARKET, BY TYPE, 20232029 (USD MILLION)
8.2 MICROBIOME CONSORTIA TRANSPLANTATION (FMT)
8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR C. DIFFICILE INFECTION TREATMENT TO AUGMENT SEGMENTAL GROWTH
TABLE 46 HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY REGION, 20232029 (USD MILLION)
TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 20232029 (USD MILLION)
TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 20232029 (USD MILLION)
TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 20232029 (USD MILLION)
8.3 PEPTIDE
8.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO GROW IN FORECAST PERIOD
TABLE 50 HUMAN MICROBIOME MARKET FOR PEPTIDE, BY REGION, 20232029 (USD MILLION)
TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 20232029 (USD MILLION)
TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 20232029 (USD MILLION)
TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 20232029 (USD MILLION)
8.4 LIVE BIOTHERAPEUTIC PRODUCT
8.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST SEGMENTAL GROWTH
TABLE 54 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY REGION, 20232029 (USD MILLION)
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 20232029 (USD MILLION)
TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 20232029 (USD MILLION)
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 20232029 (USD MILLION)
8.5 OTHERS
8.5.1 INCREASING FOCUS ON SMALL MOLECULES TO PROPEL SEGMENTAL GROWTH
TABLE 58 HUMAN MICROBIOME MARKET FOR OTHERS, BY REGION, 20232029 (USD MILLION)
TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 20232029 (USD MILLION)
TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 20232029 (USD MILLION)
TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 20232029 (USD MILLION)
9 HUMAN MICROBIOME MARKET, BY PRODUCT (Page No. - 85)
9.1 INTRODUCTION
TABLE 62 HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
9.2 DRUGS
9.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS IN PIPELINE TO DRIVE SEGMENT GROWTH
TABLE 63 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 20232029 (USD MILLION)
TABLE 64 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 65 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 66 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 20232029 (USD MILLION)
9.3 DIAGNOSTIC TESTS
9.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME- BASED TESTS TO DRIVE SEGMENT GROWTH
TABLE 67 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 20232029 (USD MILLION)
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 20232029 (USD MILLION)
9.4 PROBIOTICS
9.4.1 ONGOING RESEARCH PROMOTING CREDIBILITY REGARDING HEALTH CLAIMS AND SAFETY OF PROBIOTICS
TABLE 71 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 20232029 (USD MILLION)
TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 20232029 (USD MILLION)
9.5 PREBIOTICS
9.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA TO DRIVE SEGMENT GROWTH
TABLE 75 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 20232029 (USD MILLION)
TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 20232029 (USD MILLION)
9.6 OTHER PRODUCTS
TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 20232029 (USD MILLION)
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 20232029 (USD MILLION)
10 HUMAN MICROBIOME MARKET, BY DISEASE (Page No. - 96)
10.1 INTRODUCTION
TABLE 83 HUMAN MICROBIOME MARKET, BY DISEASE, 20232029 (USD MILLION)
10.2 INFECTIOUS DISEASES
10.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE SEGMENT GROWTH
TABLE 84 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
TABLE 85 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 20232029 (USD MILLION)
TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20232029 (USD MILLION)
TABLE 87 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20232029 (USD MILLION)
TABLE 88 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20232029 (USD MILLION)
10.3 GASTROINTESTINAL DISEASES
10.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE SEGMENT GROWTH
TABLE 89 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 20232029 (USD MILLION)
TABLE 90 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 20232029 (USD MILLION)
TABLE 91 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 20232029 (USD MILLION)
TABLE 92 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 20232029 (USD MILLION)
10.4 ENDOCRINE & METABOLIC DISORDERS
10.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO DRIVE SEGMENT GROWTH
TABLE 93 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR METABOLIC DISEASES
TABLE 94 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 20232029 (USD MILLION)
TABLE 95 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 96 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 20232029 (USD MILLION)
TABLE 97 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 20232029 (USD MILLION)
10.5 CANCER
10.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN TREATMENT OF PELVIC AND COLON CANCER
TABLE 98 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 20232029 (USD MILLION)
TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 20232029 (USD MILLION)
TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 20232029 (USD MILLION)
TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 20232029 (USD MILLION)
10.6 OTHER DISEASES
TABLE 102 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 20232029 (USD MILLION)
TABLE 103 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 20232029 (USD MILLION)
TABLE 104 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 20232029 (USD MILLION)
TABLE 105 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 20232029 (USD MILLION)
11 HUMAN MICROBIOME MARKET, BY REGION (Page No. - 107)
11.1 INTRODUCTION
TABLE 106 HUMAN MICROBIOME MARKET, BY REGION, 20232029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 107 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 108 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 109 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 110 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 20232029 (USD MILLION)
11.2.1 US
11.2.1.1 Increasing investments by NIH in support of microbiome research to drive market growth
TABLE 111 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 112 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 113 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Increasing government support and funds to support market growth
TABLE 114 INDICATIVE LIST OF PROJECTS ON HUMAN MICROBIOME IN 2018
TABLE 115 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 116 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 117 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3 EUROPE
FIGURE 17 EUROPE: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 118 EU MICROBIOME PROJECT
TABLE 119 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 120 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 121 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 122 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 20232029 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Extended applications of microbiome research to therapeutic areas to boost adoption of microbiome-based products
TABLE 123 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 124 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 125 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3.2 UK
11.3.2.1 Increasing focus on microbiome-based products development to drive market growth
TABLE 126 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 127 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 128 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Increasing funding to boost microbiome-based products development
TABLE 129 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 130 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 131 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3.4 ROE
TABLE 132 ROE: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 133 ROE: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 134 ROE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 18 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 136 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 137 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 20232029 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Large number of human microbiome research studies to drive market growth
TABLE 139 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA
TABLE 140 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 141 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 142 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth
TABLE 143 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 144 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 145 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Government funding to drive microbiome-based products development
TABLE 146 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 147 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 148 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 149 ROAPAC: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 150 ROAPAC: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 151 ROAPAC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.5 REST OF THE WORLD (ROW)
TABLE 152 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 20232029 (USD MILLION)
TABLE 153 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION, 20232029 (USD MILLION)
TABLE 154 ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 133)
12.1 OVERVIEW
12.2 PRODUCT TYPE FOOTPRINT OF COMPANIES
TABLE 155 PRODUCT TYPE PORTFOLIO ANALYSIS: HUMAN MICROBIOME MARKET (2021)
12.3 CLINICAL PHASE FOOTPRINT OF COMPANIES
TABLE 156 CLINICAL PHASE FOOTPRINT OF COMPANIES: HUMAN MICROBIOME MARKET (2021)
12.4 DISEASE FOOTPRINT OF COMPANIES
TABLE 157 DISEASE FOOTPRINT OF COMPANIES: HUMAN MICROBIOME MARKET (2021)
12.5 COMPETITIVE SCENARIO
TABLE 158 HUMAN MICROBIOME MARKET: KEY DEALS, JANUARY 2020JANUARY 2021
13 COMPANY PROFILES (Page No. - 137)
13.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ENTEROME
TABLE 159 ENTEROME: BUSINESS OVERVIEW
13.1.2 SERES THERAPEUTICS
TABLE 160 SERES THERAPEUTICS: BUSINESS OVERVIEW
FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2021)
13.1.3 4D PHARMA PLC
TABLE 161 4D PHARMA PLC: BUSINESS OVERVIEW
FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2020)
13.1.4 INTERNATIONAL FLAVORS & FRAGRANCES INC.
TABLE 162 INTERNATIONAL FLAVORS & FRAGRANCES INC.: BUSINESS OVERVIEW
FIGURE 21 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2021)
13.1.5 OPTIBIOTIX HEALTH PLC.
TABLE 163 OPTIBIOTIX HEALTH PLC.: BUSINESS OVERVIEW
FIGURE 22 OPTIBIOTIX HEALTH PLC.: COMPANY SNAPSHOT (2020)
TABLE 164 PRODUCT LAUNCHES
13.1.6 SYNLOGIC, INC.
TABLE 165 SYNLOGIC: BUSINESS OVERVIEW
FIGURE 23 SYNLOGIC, INC.: COMPANY SNAPSHOT (2020)
13.1.7 SECOND GENOME INC.
TABLE 166 SECOND GENOME INC.: BUSINESS OVERVIEW
13.1.8 VEDANTA BIOSCIENCES, INC.
TABLE 167 VEDANTA BIOSCIENCES, INC.: BUSINESS OVERVIEW
13.1.9 FERRING PHARMACEUTICALS
TABLE 168 FERRING PHARMACEUTICALS: BUSINESS OVERVIEW
13.1.10 EVELO BIOSCIENCES, INC.
TABLE 169 EVELO BIOSCIENCES: BUSINESS OVERVIEW
FIGURE 24 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
13.1.11 BIOMX
TABLE 170 BIOMX: BUSINESS OVERVIEW
FIGURE 25 BIOMX: COMPANY SNAPSHOT (2020)
13.1.12 YSOPIA BIOSCIENCE
TABLE 171 YSOPIA BIOSCIENCE: BUSINESS OVERVIEW
13.1.13 KALEIDO BIOSCIENCES, INC.
TABLE 172 KALEIDO BIOSCIENCES, INC.: BUSINESS OVERVIEW
FIGURE 26 KALEIDO BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
13.1.14 FLIGHTPATH BIOSCIENCES, INC.
TABLE 173 FLIGHTPATH BIOSCIENCES, INC.: BUSINESS OVERVIEW
13.1.15 FINCH THERAPEUTICS GROUP, INC.
TABLE 174 FINCH THERAPEUTICS GROUP, INC.: BUSINESS OVERVIEW
FIGURE 27 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2020)
13.1.16 QUANTBIOME, INC. (DBA OMBRE)
TABLE 175 QUANTBIOME, INC.: BUSINESS OVERVIEW
13.1.17 VIOME LIFE SCIENCES, INC.
TABLE 176 VIOME LIFE SCIENCES, INC.: BUSINESS OVERVIEW
13.1.18 BIOHM HEALTH
TABLE 177 BIOHM HEALTH: BUSINESS OVERVIEW
13.2 OTHER COMPANIES
13.2.1 DAYTWO
TABLE 178 DAYTWO: COMPANY OVERVIEW
13.2.2 ATLAS BIOMED
TABLE 179 ATLAS BIOMED: COMPANY OVERVIEW
13.2.3 BIONE
TABLE 180 BIONE: COMPANY OVERVIEW
13.2.4 LUXIA SCIENTIFIC
TABLE 181 LUXIA SCIENTIFIC: COMPANY OVERVIEW
13.2.5 METABIOMICS
TABLE 182 METABIOMICS: COMPANY OVERVIEW
13.2.6 SUN GENOMICS
TABLE 183 SUN GENOMICS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 182)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources such as the World Health Organization (WHO), Human Microbiome Project (HMP), Organization for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Expert Interviews, and MarketsandMarkets Analysis; business magazines and research journals; press releases; and trade, business, and professional associations.
Secondary data was collected and analyzed to arrive at the global human microbiome market's overall size, which was validated through primary research.
Primary Research
In the primary research process, various sources from the supply sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, technology & innovation directors, personnel from research organizations, physicians, academic institutes, and related key executives from various key companies and organizations operating in the human microbiome market.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the global potential market size for the human microbiome was calculated using the epidemiology approach.
- Key indications were identified for which microbiome therapy clinical trials are underway
- For respective disease categories, estimating the potential market for microbiome-based drugs from existing non-microbiome-based drugs market Microbiome therapeutics are likely to be adopted by a set of patients who show side-effects for existing therapies. Therefore, the percentage of the patient population showing some side-effects with existing therapies was identified. This percentage was then applied to the total therapy market to derive the human microbiome's total addressable market.
- To calculate the total market for microbiome therapy, the penetration rate for microbiome therapies was applied to the total addressable market
- Primary experts then validated this approach.
Individual shares of each product, disease, region, and application were arrived at based on parameters such as product pipeline, clinical trials progress, target indications, funding scenario, and research intensity in the microbiome.
Data Triangulation
After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the human microbiome market.
Report Objectives
- To define, describe, segment, and forecast the human microbiome market based on product, application, disease, and region
- To define, describe, segment, and forecast the human microbiome research spending market based on technology
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 and subsegments with respect to individual growth trends, prospects, and contributions to the overall human microbiome market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments concerning four main regions (along with countries), namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (South America, Latin America, and the Middle East & Africa)
- To strategically analyze the market structure and profile the key players of the global human microbiome market and comprehensively analyze their core competencies2
- To track and analyze competitive developments such as acquisitions; partnerships, agreements, & collaborations; and product launches in the human microbiome market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs.
The following customization option is available for the report:
Additional Company Profiles
- Company profiles for five additional companies.
Human Microbiome Market News
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
Growth opportunities and latent adjacency in Human Microbiome Market